Syndax Pharmaceuticals Inc Stock Price, News & Analysis

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the appointment of Keith A. Goldan as Chief Financial Officer. Goldan, with nearly 30 years of experience in the pharmaceutical sector, previously served as CFO at Optinose, assisting in the launch of XHANCE. CEO Michael A. Metzger emphasized Goldan's expertise as crucial for the company's growth. The press release also highlighted upcoming pivotal readouts for revumenib and axatilimab, both targeting significant cancer treatment needs. Additionally, Sharon Klahre was appointed Vice President of Investor Relations.

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced participation in two investor conferences. Management will engage in a virtual fireside chat at Cowen's 3rd Annual Oncology Innovation Summit on June 2, 2022, at 12:30 p.m. ET. Additionally, they will partake in a fireside chat at Goldman Sachs' 43rd Annual Global Healthcare Conference on June 14, 2022, at 6:20 p.m. ET in Rancho Palos Verdes, CA. Live webcasts of both events will be accessible on their website, along with a limited-time replay.

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical firm focused on cancer therapies, announced CEO Michael A. Metzger's participation in a targeted oncology panel at Citi's Biopharma Virtual Co-Panel Day on May 18, 2022, at 1:30 p.m. ET. The event will highlight the company's innovative drug pipeline, including revumenib and axatilimab, which are currently in pivotal trials. A live webcast of the panel will be available on their website, along with a replay for limited access.

Syndax Pharmaceuticals (SNDX) reported its Q1 2022 financial results, revealing a net loss of $37.2 million or $0.63 per share, up from a loss of $27.7 million or $0.54 per share in Q1 2021. Research and development expenses rose to $30 million from $21.9 million due to increased clinical activities. The company is advancing its pivotal trials for revumenib (SNDX-5613) and axatilimab, with topline data expected in 1H23 and two FDA filings planned for 2023. As of March 31, 2022, Syndax had $397.9 million in cash and equivalents.

Syndax Pharmaceuticals (SNDX) will release its first quarter 2022 financial results on May 9, 2022, after U.S. market close. A conference call and audio webcast will follow at 4:30 p.m. ET to discuss the results and business updates. Interested parties can access the webcast on the company's website. Syndax's pipeline includes promising cancer therapies such as SNDX-5613, a Menin–MLL inhibitor, axatilimab, a CSF-1 receptor blocker, and entinostat, a class I HDAC inhibitor.

Syndax Pharmaceuticals announced an inducement award for its new Chief Medical Officer, Dr. Catherine Madigan, granting her the option to purchase 180,000 shares of common stock at an exercise price of $16.06, equal to the closing stock price on March 1, 2022. This option will vest over four years, with a quarter vesting after one year and the remainder vesting monthly after that. The award, approved by Syndax's Board of Directors, complies with NASDAQ Listing Rule 5635(c)(4). Syndax is developing a pipeline of innovative cancer therapies including SNDX-5613 and axatilimab.

Syndax Pharmaceuticals reported strong fourth-quarter results for 2021. The company recorded a net profit of $96.2 million, or $1.81 per share, compared to a loss of $20.4 million in the same period last year. License revenue surged to $126.6 million due to a collaboration with Incyte. Syndax outlined significant progress in its clinical pipeline, expecting topline data from pivotal trials in 2023. Cash and equivalents stood at $439.9 million, providing ample runway for ongoing research and development.

Syndax Pharmaceuticals (SNDX) appointed Kate Madigan, M.D., as Chief Medical Officer, effective immediately. Dr. Madigan brings over 20 years of clinical hematology expertise and will lead the clinical development strategy at Syndax. She succeeds Michael Meyers, M.D., Ph.D., who will transition to a consulting role. Under her leadership, Syndax expects to advance its pipeline, which includes SNDX-5613 and axatilimab, with pivotal FDA filings anticipated next year, positioning the company to impact underserved cancer treatment areas.

Syndax Pharmaceuticals announced participation in two investor conferences: a panel at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 10:30 a.m. ET, and a presentation at the Barclays Global Healthcare Conference on March 16, 2022, at 3:50 p.m. ET. Both events will be available via live webcast on www.syndax.com, along with replays. Syndax is advancing an innovative cancer therapy pipeline, including SNDX-5613, axatilimab, and entinostat. These events aim to engage investors and communicate the company’s progress in developing cancer treatments.